Skip to Content

News & Events

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences
CAMBRIDGE, Mass., Jun 01, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will webcast its presentations at the Bear Stearns Biotech Confab on Thursday, June 7th at 7:50 a.m. EDT and at the Goldman Sachs 28th Annual Global Healthcare Conference on Wednesday, June 13th at
View HTML
Toggle Summary Stockholders of Vertex Pharmaceuticals Re-elect Directors at Annual Meeting
CAMBRIDGE, Mass., May 31, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results of the voting at its 2007 Annual Meeting of Stockholders. At the meeting, stockholders re-elected Joshua Boger, Ph.D., Charles A. Sanders, M.D., and Elaine S.
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Webcast of its Presentation at Citigroup's 2007 Global Healthcare Conference
CAMBRIDGE, Mass., May 17, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will webcast its presentation at Citigroup's 2007 Global Healthcare Conference on May 23, 2007 at 4:00 p.m. EDT. The presentation will be webcast live and may be accessed from the 'Events Calendar'
View HTML
Toggle Summary Vertex Pharmaceuticals Reports First Quarter 2007 Financial Results
CAMBRIDGE, Mass., Apr 30, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended March 31, 2007. "In 2007, a major goal for Vertex is to build the product profile of the investigational hepatitis C protease
HCV
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences
CAMBRIDGE, Mass., Apr 26, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will webcast its presentations at the Morgan Stanley Global Healthcare Unplugged Conference on May 2, 2007 at 2:15 p.m. EDT and at Deutsche Bank's 32nd Annual Health Care Conference on May 3, 2007
View HTML
Toggle Summary Interim Results Presented at EASL from PROVE 1 Clinical Trial of Investigational Drug Telaprevir in Patients with Genotype 1 Hepatitis C
-- PROVE 1 data support potential to shorten treatment duration in treatment-naive, genotype 1 HCV patients --
HCV
View HTML
Toggle Summary Vertex Pharmaceuticals Announces New Data for Investigational HCV Protease Inhibitor Telaprevir to be Presented at 42nd Annual Meeting of the European Association for the Study of the Liver (EASL)
In vitro results support expansion of telaprevir clinical development into genotype 2, 3 and 4 HCV patients
HCV
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences
CAMBRIDGE, Mass., Mar 07, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will webcast its presentations at the Cowen and Company 27th Annual Health Care Conference on March 13, 2007 at 8:45 a.m. EDT and at the Citigroup Small & Mid-Cap Conference on March 14, 2007 at
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Completion of Conversion of Outstanding 5.75% Convertible Senior Subordinated Notes due 2011
CAMBRIDGE, Mass., Mar 05, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that in connection with the previously announced redemption of its 5.75% Convertible Senior Subordinated Notes due 2011, holders of all of the outstanding notes converted their notes
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Webcast of its Presentation at the Bear Stearns Ninth Annual London Healthcare Conference
CAMBRIDGE, Mass., Feb 22, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will webcast its corporate presentation at the Bear Stearns Ninth Annual London Healthcare Conference on Tuesday, February 27, 2007 at 11:20 a.m. GMT (6:20 a.m. EST).
View HTML